Repository logo
 

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.

Simple item page
dc.contributor.authorRovin, Brad H
dc.contributor.authorAdler, Sharon G
dc.contributor.authorBarratt, Jonathan
dc.contributor.authorBridoux, Frank
dc.contributor.authorBurdge, Kelly A
dc.contributor.authorChan, Tak Mao
dc.contributor.authorCook, H Terence
dc.contributor.authorFervenza, Fernando C
dc.contributor.authorGibson, Keisha L
dc.contributor.authorGlassock, Richard J
dc.contributor.authorJayne, David RW
dc.contributor.authorJha, Vivekanand
dc.contributor.authorLiew, Adrian
dc.contributor.authorLiu, Zhi-Hong
dc.contributor.authorMejía-Vilet, Juan M
dc.contributor.authorNester, Carla M
dc.contributor.authorRadhakrishnan, Jai
dc.contributor.authorRave, Elizabeth M
dc.contributor.authorReich, Heather N
dc.contributor.authorRonco, Pierre
dc.contributor.authorSanders, Jan-Stephan F
dc.contributor.authorSethi, Sanjeev
dc.contributor.authorSuzuki, Yusuke
dc.contributor.authorTang, Sydney CW
dc.contributor.authorTesar, Vladimír
dc.contributor.authorVivarelli, Marina
dc.contributor.authorWetzels, Jack FM
dc.contributor.authorLytvyn, Lyubov
dc.contributor.authorCraig, Jonathan C
dc.contributor.authorTunnicliffe, David J
dc.contributor.authorHowell, Martin
dc.contributor.authorTonelli, Marcello A
dc.contributor.authorCheung, Michael
dc.contributor.authorEarley, Amy
dc.contributor.authorFloege, Jürgen
dc.contributor.orcidJayne, David [0000-0002-1712-0637]
dc.date.accessioned2021-11-11T00:30:29Z
dc.date.available2021-11-11T00:30:29Z
dc.date.issued2021-10
dc.description.abstractThe Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (GN), both adults and children. The scope includes various glomerular diseases, including IgA nephropathy and IgA vasculitis, membranous nephropathy, nephrotic syndrome, minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), infection-related GN, antineutrophil cytoplasmic antibody (ANCA) vasculitis, lupus nephritis, and anti-glomerular basement membrane antibody GN. In addition, this guideline will be the first to address the subtype of complement-mediated diseases. Each chapter follows the same format providing guidance related to diagnosis, prognosis, treatment, and special situations. The goal of the guideline is to generate a useful resource for clinicians and patients by providing actionable recommendations based on evidence syntheses, with useful infographics incorporating views from experts in the field. Another aim is to propose research recommendations for areas where there are gaps in knowledge. The guideline targets a broad global audience of clinicians treating GN while being mindful of implications for policy and cost. Development of this guideline update followed an explicit process whereby treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the quality of the evidence and the strength of recommendations followed the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. Limitations of the evidence are discussed, with areas of future research also presented.
dc.format.mediumPrint
dc.identifier.doi10.17863/CAM.77993
dc.identifier.eissn1523-1755
dc.identifier.issn0085-2538
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/330549
dc.languageeng
dc.language.isoeng
dc.publisherElsevier BV
dc.publisher.urlhttp://dx.doi.org/10.1016/j.kint.2021.05.015
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAAV
dc.subjectANCA
dc.subjectC3
dc.subjectFSGS
dc.subjectIgA nephropathy
dc.subjectIgA vasculitis
dc.subjectKDIGO
dc.subjectMPGN
dc.subjectanti-GBM
dc.subjectcomplement
dc.subjectevidence-based
dc.subjectglomerular diseases
dc.subjectglomerulonephritis
dc.subjectguideline
dc.subjectinfection-related glomerulonephritis
dc.subjectlupus nephritis
dc.subjectmembranous nephropathy
dc.subjectminimal change disease
dc.subjectnephrotic syndrome
dc.subjectsystematic review
dc.subjectAdult
dc.subjectChild
dc.subjectGlomerulonephritis
dc.subjectGlomerulonephritis, IGA
dc.subjectGlomerulonephritis, Membranous
dc.subjectHumans
dc.subjectKidney
dc.subjectNephrosis, Lipoid
dc.titleExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
dc.typeArticle
dcterms.dateAccepted2021-05-20
prism.endingPage779
prism.issueIdentifier4
prism.publicationDate2021
prism.publicationNameKidney Int
prism.startingPage753
prism.volume100
rioxxterms.licenseref.startdate2021-10
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1016/j.kint.2021.05.015

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Executive summary of the KDIGO 2021 Guidelines for the Management of Glomerular Diseases.pdf
Size:
14.57 MB
Format:
Adobe Portable Document Format
Description:
Published version
Licence
https://creativecommons.org/licenses/by-nc-nd/4.0/
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
DepositLicenceAgreementv2.1.pdf
Size:
150.9 KB
Format:
Adobe Portable Document Format
Download

Collections

Cambridge University Research Outputs